ArticleAntimicrobial agents and chemotherapy2018
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting ClpP Protease: Emerging Therapeutic Strategies and Small-Molecule Modulators in Drug Discovery.Medicinal research reviews · 2026Review
- Repurposing Birabresib to target Gram‑positive bacteria.npj antimicrobials and resistance · 2026Article
- Article
- Sophisticated natural products as antibiotics.Nature · 2024Review
- Bacteriophage endolysin Ply113 as a potent antibacterial agent against polymicrobial biofilms formed byFrontiers in microbiology · 2023Article
- Membrane-Active Cyclic Amphiphilic Peptides: Broad-Spectrum Antibacterial Activity Alone and in Combination with Antibiotics.Journal of medicinal chemistry · 2022Article
- Recent structural insights into the mechanism of ClpP protease regulation by AAA+ chaperones and small molecules.The Journal of biological chemistry · 2022Review
- Alternatives to Fight Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- β-Lactams against the Fortress of the Gram-PositiveChemical reviews · 2021Review
- Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions.Infection and immunity · 2021Review
- Article
- Reprogramming of the Caseinolytic Protease by ADEP Antibiotics: Molecular Mechanism, Cellular Consequences, Therapeutic Potential.Frontiers in molecular biosciences · 2021Review
- Antimicrobial resistance in enteric bacteria: current state and next-generation solutions.Gut microbes · 2020Review
- Functional Characterisation of ClpP Mutations Conferring Resistance to Acyldepsipeptide Antibiotics in Firmicutes.Chembiochem : a European journal of chemical biology · 2020Article
- Cell Division Protein FtsZ Is Unfolded for N-Terminal Degradation by Antibiotic-Activated ClpP.mBio · 2020Article
- Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.International journal of antimicrobial agents · 2020Article
- Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.Antimicrobial agents and chemotherapy · 2019Article
- Ureadepsipeptides as ClpP Activators.ACS infectious diseases · 2019Article
- The ADEP Biosynthetic Gene Cluster in Streptomyces hawaiiensis NRRL 15010 Reveals an AccessoryApplied and environmental microbiology · 2019Article
- The functional ClpXP protease of Chlamydia trachomatis requires distinct clpP genes from separate genetic loci.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Antibiotics with novel bactericidal mechanisms of action are urgently needed. The antibiotic acyldepsipeptide 4 (ADEP4) activates the ClpP protease and causes cells to self-digest. The effects of ADEP4 and ClpP activation have not been characterized sufficiently for the enterococci, which are important pathogens known for high levels of acquired and intrinsic antibiotic resistance. In the present study, ADEP4 was found to be potently active against both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.